By using our site you accept the terms of our cookie policy

Search

GHP July 2016

July 26, 2016

A very warm welcome to the July 2016 edition of Global Health & Pharma, which begins on an upbeat note with breaking health news from the UK Government, the Northern Ireland Executive, the Scottish Government and the National Assembly for Wales.

Speaking at a major conference in Cardiff, Welsh Government Cabinet Secretary for Health Vaughan Gething, recently raised awareness of the excellent employment careers that exist within NHS Wales. And Northern Ireland Health Minister Michelle O’Neill in late June set out her ambitious priorities for the next phase of reform of health and social care.

In major news, the implementation of Scotland’s £100 million cancer strategy will drive improvements in access to cancer care, Health Secretary Shona Robison said in June. The strategy will invest in the prevention, detection, diagnosis, treatment and aftercare for cancer patients – as well improving treatment waiting times.

In other news, we reveal the findings of a new report published in May, The Global Market for Population Health Management, which claims that the cumulative global economic burden of chronic disease is estimated to rise to be around US$240 trillion between 2013 and 2025. The need for solutions to the escalation in healthcare costs is being experienced within both the government and the corporate sectors in almost all countries worldwide.

Moving to the subject of technology, respected Frost & Sullivan Senior Research Analyst Tanvir Jaikishen reveals that the accelerated adoption of new technologies, therapeutic applications and innovative business models will certainly impact the European Healthcare Industry of the future.

In a special guest article, Dr Michael Sinclair and Josie Seydel, authors of the book Working with Mindfulness discuss the shift towards compassion in business, and how this can be summed up on a macro level by looking at how we can ensure that businesses are thriving rather than simply surviving. 

I hope you enjoy reading this compelling edition.

Contact Us

+44 (0) 203 725 6847